Breast Cancer Survivors
Conditions
Keywords
Asprin, Omega-3 Free Fatty Acids, Obesity, COX-2 inhibitor
Brief summary
Obesity promotes worse outcome for post-menopausal breast cancer patients.
Interventions
DRUGAspirin
DIETARY_SUPPLEMENTOmega 3 FFA
Sponsors
The University of Texas Health Science Center at San Antonio
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* At least 18 years of age * Post-menopausal as confirmed by medical history * Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
Exclusion criteria
* Evidence of active cancer (patients with a prior history of malignancy are encouraged to participate, but due to cytokine levels associated with malignancy there must be no evidence of disease) * Cachexia * Active systemic illness (infection including viral illnesses such as Hepatitis and HIV) * Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days) * Known hypersensitivity to aspirin and/or omega-3 fatty acids * Actively receiving a physician-directed regimen of aspirin and/or receiving herapeutic/prophylactic anticoagulation * Any aspirin or omega-3 free fatty acid supplementation within the last 14 days * Subjects who are pregnant * History of medical noncompliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker levels | 29 days | Blood levels of Prostaglandin E2, aromatase, pro-inflammatory cytokines, steroids, and lipids will be measured pre and post treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BMI | 29 Days | Correlation for body mass index impact on response to COX2 inhibition. |
Countries
United States
Outcome results
None listed